ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Genentech’s Esbriet gets FDA breakthrough status in uILD pharmaceutical-technology
March 05, 2020Roche Group unit Genentech has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for Esbriet (pirfenidone) to treat unclassifiable interstitial lung disease (uILD) in adults.
Pharma Sources Insight January 2025
